Simeprevir Clears FDA, But Tougher Road Lies Ahead
This article was originally published in The Pink Sheet Daily
Unlike HCV competitors Incivek and Victrelis, Janssen’s second-generation protease inhibitor Olysio carries a recommendation for screening to weed out patients with a hepatitis C variant associated with poor response – but the strength of its efficacy and safety should still beat out those drugs. The harder part will be gaining share as patients are opting to wait for even better regimens.
You may also be interested in...
For Vertex, the key question is how much is physician and patient concern about the adverse events is already reflected in the softening sales of the hepatitis C drug; for FDA, the question is how effective will label-based risk management be.
A new analysis from BIO, Informa Pharma Intelligence and QLS looks at clinical drug development activity from the past decade, looking at the most (and least) successful areas. Infographic depicts key trends and details.
Breyanzi’s list price is $410,300. The CD19-targeting CAR-T therapy previously known as liso-cel has a lot of ground to make up following competitors Yescarta and Kymriah.